Tissium

TISSIUM is a private, clinical-stage medtech company pioneering a platform of biomorphic programmable polymers for tissue reconstruction. The company has achieved its first commercial milestone with the FDA De Novo authorization of COAPTIUM® CONNECT for sutureless nerve repair in the United States. With an integrated innovation and manufacturing platform, TISSIUM is advancing a pipeline across peripheral nerve, cardiovascular, and gastrointestinal therapeutic areas, leveraging both internal development and industry co-development partnerships. The company represents a convergence of advanced material science and surgical device development.

A proprietary platform of biomorphic programmable polymers, combined with activation technologies and delivery devices. The polymers are engineered to conform to and integrate with native tissue, and their properties can be adjusted (programmed) for specific tissue requirements.

Faces competition from established surgical suture, mesh, and sealant companies (e.g., Johnson & Johnson, Medtronic, Baxter) in soft tissue repair. In nerve repair, it competes with traditional microsutures and existing nerve wrap/cuff products. Its key differentiation is the biomorphic, programmable nature of its polymer platform, aiming for superior integration and tailored performance.